亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口返回主站||保存桌面|手機瀏覽|聯系方式|購物車

企業會員第1年

榮大醫藥化工有限公司

阿那曲唑，拉帕替尼，伊班膦酸鈉，氟維司群，恩替卡韋，鹽酸帕洛諾司瓊，索拉菲尼，鹽酸美金剛胺，鹽酸米那普倫，利托那韋中間體，胡椒酸，伊馬替尼，來曲唑，磷酸奧司他韋等

網站公告

阿那曲唑，拉帕替尼，伊班膦酸鈉，氟維司群，恩替卡韋，鹽酸帕洛諾司瓊，索拉菲尼，鹽酸美金剛胺，鹽酸米那普倫，利托那韋中間體，胡椒酸，伊馬替尼，來曲唑，磷酸奧司他韋等

新聞中心

暫無新聞

產品分類

聯系方式

聯系人：黎女士
電話：0571-28182190
郵件：shelly@rdpharm.com
傳真：0571-28281887
QQ：1833436340

站內搜索

榮譽資質

暫未上傳

友情鏈接

暫無鏈接

首頁 > 供應產品 > 美金剛胺 Memantine 41100-52-1

美金剛胺 Memantine 41100-52-1

單價	￥1.00 / kg對比
詢價	暫無
發貨	浙江湖州市付款后3天內
庫存	1111kg
品牌	榮大
型號	41100-52-1
規格	99
過期	長期有效
更新	2014-03-25 13:24

詳細信息


基本信息
英文名		Memantine hydrochloride
別名		1,3-Dimethylaminoadamantane hydrochloride; 3,5-Dimethyl-1-aminoadamantane hydrochloride; 3,5-Dimethyltricyclo(3.3.1.1(3,7))decan-1-amine hydrochloride


分子結構

分子式		C₁₂H₂₁N^.HCl
分子量		215.77
CAS 登錄號		41100-52-1
EINECS 登錄號		255-219-6

©2025 榮大醫藥化工有限公司版權所有技術支持：化工網訪問量:7275

主站蜘蛛池模板： | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |